OOIR: Observatory of International Research

Papers

(The TQCC of Pharmacology & Therapeutics is 33. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)

Article	Citations
Editorial Board	409
Efficacy and safety of immune-modulating therapy for primary sclerosing cholangitis: A systematic review and meta-analysis	407
Adenosine receptor signalling as a driver of pulmonary fibrosis	340
WITHDRAWN: 17th International conference on bioactive lipids in cancer, inflammation and related diseases virtual special issue	270
Unlocking the power of affibody conjugated radioactive metallopharmaceuticals for targeted cancer diagnosis and therapy	263
Treatment strategies for leptomeningeal disease in patients with breast cancer	250
Inflammation, lipids, and pain in vulvar disease	225
Measuring brain docosahexaenoic acid turnover as a marker of metabolic consumption	206
Matrikines in the skin: Origin, effects, and therapeutic potential	190
HIV-associated neurotoxicity and cognitive decline: Therapeutic implications	183
Unfolded protein responses: Dynamic machinery in wound healing	164
SGLT2 inhibitors: Do they have antiarrhythmic properties?	162
Non-canonical G protein signaling	149
Collateral lethality: A unique type of synthetic lethality in cancers	116
Treatment approaches for alcohol use disorder with metabolic dysfunction	114
Potential neonatal toxicity of new psychoactive substances	114
The role of macrophages in asthma-related fibrosis and remodelling	110
Retinoid dynamics in vision: from visual cycle biology to retina disease treatments	109
Lipid metabolism in AKI and AKI-CKD transition: Dysregulation, lipotoxicity and therapeutic potential	108
New therapeutic horizons for plasma phospholipid transfer protein (PLTP): Targeting endotoxemia, infection and sepsis	107
Endothelial dysfunction as a complication of anti-cancer therapy	106
Regulatory lipid vicinal diols counteract the biological activity of epoxy fatty acids and can act as biomarkers and mechanisms for disease progression	105
Targeting the p38α pathway in chronic inflammatory diseases: Could activation, not inhibition, be the appropriate therapeutic strategy?	104
Pharmacological modulation of respiratory control: Ampakines as a therapeutic strategy	103
Sulfoconjugation of protein peptides and glycoproteins in physiology and diseases	99

Novel strategies and promising opportunities for targeted protein degradation: An innovative therapeutic approach to overcome cancer resistance	97
Boron in cancer therapeutics: An overview	95
Imaging neuroinflammation with TSPO: A new perspective on the cellular sources and subcellular localization	93
Management of drug-resistant hypertension as a heterogeneous disorder	85
Editorial Board	85
Novel approaches to target fibroblast mechanotransduction in fibroproliferative diseases	85
TAAR1 as an emerging target for the treatment of psychiatric disorders	85
Harnessing and delivering microbial metabolites as therapeutics via advanced pharmaceutical approaches	83
Recent drug design strategies and identification of key heterocyclic scaffolds for promising anticancer targets	83
Myeloid cells in the era of cancer immunotherapy: Top 3 unanswered questions	83
Is the peroxisome proliferator-activated receptor gamma a putative target for epilepsy treatment? Current evidence and future perspectives	80
The phospholipase A2 superfamily as a central hub of bioactive lipids and beyond	80
Dysregulation of metabolic pathways in pulmonary fibrosis	79
Editorial Board	78
Corrigendum to “The role of CD71+ erythroid cells in the regulation of the immune response” [Pharmacology & Therapeutics 228 (2021) 107927]	78
Editorial Board	77
N6-methyladenosine (m6A) RNA methylation: a potential clinical therapeutic target in cardiocerebrovascular diseases	76
PGRMC1: An enigmatic heme-binding protein	74
Therapeutic implications of impaired nuclear receptor function and dysregulated metabolism in Wilson's disease	73
Recent advances in metabolism and toxicity of tyrosine kinase inhibitors	72
Pharmacological treatment of cardiogenic shock – A state of the art review	71
Review: Sex-related differences in the treatment of cardiac arrhythmia	71
Natural products that alleviate depression: The putative role of autophagy	70
The pathomimetic oAβ25–35 model of Alzheimer's disease: Potential for screening of new therapeutic agents	70
Bispecific antibodies for the treatment of neuroblastoma	68
Interactions between NSAIDs, opioids and the gut microbiota - Future perspectives in the management of inflammation and pain	68
DNA methylation in cell plasticity and malignant transformation in liver diseases	67
Drug-drug interactions that alter the exposure of glucuronidated drugs: Scope, UDP-glucuronosyltransferase (UGT) enzyme selectivity, mechanisms (inhibition and induction), and clinical significance	67
A dive into the untapped potential of marine compounds in counteracting neurodegeneration	67
Stabilizing the neural barrier – A novel approach in pain therapy	66
Unravelling the complexity of cancer premetastatic niche - Mechanistic insights and clinical therapies	65
Air pollution and diseases: signaling, G protein-coupled and Toll like receptors	64
Targeting mGluR2/3 for treatment of neurodegenerative and neuropsychiatric diseases	64
A systematic review on renal effects of SGLT2 inhibitors in rodent models of diabetic nephropathy	63
CircRNAs as upstream regulators of miRNA//HMGA2 axis in human cancer	62
Autophagy inhibitors for cancer therapy: Small molecules and nanomedicines	60
Entering the TiME machine: How age-related changes in the tumor immune microenvironment impact melanoma progression and therapy response	60
HDL-based therapeutics: A promising frontier in combating viral and bacterial infections	60
Advances in pathogenesis and therapeutic strategies for osteoporosis	59
The role of microglia heterogeneity in synaptic plasticity and brain disorders: Will sequencing shed light on the discovery of new therapeutic targets?	59
Drug-induced Torsades de pointes: Insights from a canine model of chronic atrioventricular block	58
MAS-related G protein-coupled receptors X (MRGPRX): Orphan GPCRs with potential as targets for future drugs	58
In vitro functional assays as a tool to study new synthetic opioids at the μ-opioid receptor: Potential, pitfalls and progress	58
Noncoding RNA circuitry in melanoma onset, plasticity, and therapeutic response	58
Editorial: Beyond the opioid crisis: New targets for the management of chronic pain	58
17β-hydroxysteroid dehydrogenases in the progression of nonalcoholic fatty liver disease	56
Neuromuscular and cardiac organoids and assembloids: Advanced platforms for drug testing	56
Recent advances in riboflavin transporter RFVT and its genetic disease	56
Endothelial shear stress signal transduction and atherogenesis: From mechanisms to therapeutics	54
Emerging roles of RNA ac4C modification and NAT10 in mammalian development and human diseases	53

Regulation of feeding and therapeutic application of bioactive peptides	53
Myeloperoxidase: Growing importance in cancer pathogenesis and potential drug target	52
Extracellular vesicles in cardiovascular disease: Biological functions and therapeutic implications	52
The role of drug-metabolizing enzymes in synthetic lethality of cancer	51
Therapeutic targeting of DNA methylation alterations in cancer	51
Chemical diversity, traditional uses, and bioactivities of Rosa roxburghii Tratt: A comprehensive review	50
Optimizing drug therapies in cardiac amyloidosis	49
Editorial Board	49
Cerebrovascular protective functions of amyloid precursor protein: Progress and therapeutic prospects	48
Cannabinoid receptor 1 ligands: Biased signaling mechanisms driving functionally selective drug discovery	48
MicroRNAs in drug addiction: Current status and future perspectives	48
The emerging science of Glioception: Contribution of glia in sensing, transduction, circuit integration of interoception	48
Update on treatment of abdominal pain in irritable bowel syndrome: A narrative review	47
Pathological changes in GPCR signal organisation: Opportunities for targeted therapies for triple negative breast cancer	47
Bridging the gap: The endocannabinoid system as a functional fulcrum for benzodiazepines in a novel frontier of anxiety pharmacotherapy	47
Corrigendum to “Drug discovery through biophysical techniques: Methods and applications” [pharmacology and therapeutics volume 277 (2026) 108947]	47
Lactate acidosis and simultaneous recruitment of TGF-β leads to alter plasticity of hypoxic cancer cells in tumor microenvironment	47
Therapeutic exploration of biased ligands at class A G protein-coupled receptors over the past 20 years	47
Hepatic solute carrier transporters and drug therapy: Regulation of expression and impact of genetic variation	46
Pharmacological potential of cyclic nucleotide signaling in immunity	46
Organic anion transporters in remote sensing and organ crosstalk	46
CDNF and ER stress: Pharmacology and therapeutic possibilities	46
Immunotherapy for hepatocellular carcinoma: Recent advances and future targets	45
Editorial Board	45
Musculoskeletal crosstalk in chronic obstructive pulmonary disease and comorbidities: Emerging roles and therapeutic potentials	45
Integrins in cancer: Emerging mechanisms and therapeutic opportunities	45
Pharmacological interventions for intraplaque neovascularization in atherosclerosis	44
G protein-coupled estrogen receptor biased signaling in health and disease	43
The role and participation of immune cells in the endometrial tumor microenvironment	43
Targeting cancer-associated fibroblasts: Challenges, opportunities and future directions	43
The tissue-specific transcriptional landscape underlines the involvement of endothelial cells in health and disease	43
Oxidative stress and antioxidant therapeutic mechanisms	42
Neurobiological mechanisms of botulinum neurotoxin-induced analgesia for neuropathic pain	42
The (neuro)inflammatory system in anxiety disorders and PTSD: Potential treatment targets	41
Editorial Board	41
Molecular mechanisms of ferroptosis and their involvement in brain diseases	41
A map of molecular drug targets and therapeutics for the US FDA-approved drugs: The impact of expedited regulatory pathways and first-in-class drug approvals on drug innovation	41
Exploring the landscape of post-translational modification in drug discovery	41
Platelet lipid metabolism in vascular thrombo-inflammation	40
Annexin A1 in neurological disorders: Neuroprotection and glial modulation	40
Development and clinical translation of P2X7 receptor antagonists: A potential therapeutic target in coronary artery disease?	40
Phosphorylation of nuclear receptors: Novelty and therapeutic implications	40
RNA renaissance: Harnessing non-coding RNA therapeutics for hepatocellular carcinoma	40
Attributes novel drug candidate: Constitutive GPCR signal bias mediated by purinergic receptors	40
Following the design path of isoform-selective Hsp90 inhibitors: Small differences, great opportunities	40
Understanding the molecular bridges between the drugs and immune cell	40
Targeting cell cycle checkpoints for glioma therapy	39
Potential targeting of the tumor microenvironment to improve cancer virotherapy	39
Editorial Board	38
Advances in anticancer alkaloid-derived metallo-chemotherapeutic agents in the last decade: Mechanism of action and future prospects	38
From bench to clinic: Emerging therapies for corneal scarring	37
Targeting the Semaphorin3E-plexinD1 complex in allergic asthma	36
Immune cells and their derived microRNA-enriched extracellular vesicles in nonalcoholic fatty liver diseases: Novel therapeutic targets	36
Prolactin and pain of endometriosis	36
Modulating glucocorticoid receptor actions in physiology and pathology: Insights from coregulators	35
Post-COVID pulmonary sequelae: Mechanisms and potential targets to reduce persistent fibrosis	35
The essential role of docosahexaenoic acid and its derivatives for retinal integrity	35
Signaling pathways in brain ischemia: Mechanisms and therapeutic implications	35
Therapeutic antibodies – natural and pathological barriers and strategies to overcome them	35
Roles of NLRC4 inflammasome in neurological disorders: Mechanisms, implications, and therapeutic potential	35
Nanotechnology and nano-sized tools: Newer approaches to circumvent oncolytic adenovirus limitations	35
Early life adversities, psychopathologies and novel pharmacological strategies	35
Plant-derived nanovesicles and therapeutic application	35
Editorial Board	34
The antidepressant actions of ketamine and its enantiomers	34
Editorial Board	34
Protoporphyrin IX-induced phototoxicity: Mechanisms and therapeutics	34
Targeting myeloid-derived suppressor cells to enhance natural killer cell-based immunotherapy	34
Chloride channels in the lung: Challenges and perspectives for viral infections, pulmonary arterial hypertension, and cystic fibrosis	33
Anti-cancer activity of sustained release capsaicin formulations	33
Biased signaling in drug discovery and precision medicine	33
Post-translational modifications of histone and non-histone proteins in epigenetic regulation and translational applications in alcohol-associated liver disease: Challenges and research opportunities	33
Distinct mechanisms underlying therapeutic potentials of CD20 in neurological and neuromuscular disease	33
Treatment of overdose in the synthetic opioid era	33